A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Key facts

Sponsor

Shanghai Tong Ren Hospital

Intervention

Selinexor(drug)

Enrollment

58 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2027

Study locations (19)

• Changzhou Municipal No.1 People's Hospital, Changzhou, China
• Sichuan Provincial People's Hospital, Chengdu, China
• Jilin University China Japan Union Hospital, Ch’ang-ch’un, China
• Harbin Institute of Hematology and Oncology, Ha’erbin, China
• Anhui Provincial Hospital, Hefei, China
• the first hospital of Jiaxing affiliated hospital of Jiaxing University, Jiaxing, China
• Gansu Provincial People's Hospital, Lanzhou, China
• Lanzhou University NO.2 Hospital, Lanzhou, China
• Ningbo Medical Center Lihuili Huspital, Ningbo, China
• Shanghai Ruijin Hospital, Shanghai, China
• Shanghai Tong Ren hospital, Shanghai, China
• The First Hospital of China Medical University, Shenyang, China
• The First Hospital of Hebei Medical University, Shijia Zhuang, China
• The Second Hospital of Hebei Medical University, Shijia Zhuang, China
• First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China
• +4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →